{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=40",
    "query": {
      "intervention": "Intermediate dose",
      "page": 40
    },
    "page_size": 10
  },
  "pagination": {
    "page": 40,
    "page_size": 10,
    "total_count": 2634,
    "total_pages": 264,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=41&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermediate+dose&page=39&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T15:06:27.051Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01422161",
      "title": "Study of Botulinum Toxin and Recovery of Hand Function After Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stroke With Hemiparesis"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin commonly known as BOTOX®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2010-04",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2019-06-20",
      "last_synced_at": "2026-10-28T15:06:27.051Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01422161"
    },
    {
      "nct_id": "NCT07548606",
      "title": "A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Opevesostat",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Fludrocortisone acetate",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "19 Years to 55 Years · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2026-05-11",
      "completion_date": "2026-06-18",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-10-28T15:06:27.051Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07548606"
    },
    {
      "nct_id": "NCT05228184",
      "title": "Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Congenital Hypothyroidism"
      ],
      "interventions": [
        {
          "name": "Tirosint®-SOL",
          "type": "DRUG"
        },
        {
          "name": "Levothyroxine Sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IBSA Institut Biochimique SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "9 Months",
        "sex": "ALL",
        "summary": "1 Day to 9 Months"
      },
      "enrollment_count": 34,
      "start_date": "2022-01-21",
      "completion_date": "2025-03-27",
      "has_results": true,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-28T15:06:27.051Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05228184"
    },
    {
      "nct_id": "NCT01416571",
      "title": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 78,
      "start_date": "2011-08-12",
      "completion_date": "2012-09-28",
      "has_results": true,
      "last_update_posted_date": "2018-09-21",
      "last_synced_at": "2026-10-28T15:06:27.051Z",
      "location_count": 1,
      "location_summary": "Mesa, Arizona",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01416571"
    },
    {
      "nct_id": "NCT03573310",
      "title": "A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Solid Tumor, Adult",
        "Non-Hodgkin Lymphoma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "JNJ-64619178",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2018-07-13",
      "completion_date": "2025-09-25",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-10-28T15:06:27.051Z",
      "location_count": 4,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03573310"
    },
    {
      "nct_id": "NCT07572513",
      "title": "Slowly Digestible Carbohydrates for GLP-1 Secretion",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blood Glucose",
        "GLP-1",
        "Satiety",
        "Second Meal Intake",
        "Healthy Participant Study"
      ],
      "interventions": [
        {
          "name": "Maltodextrin (Placebo)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Raw Corn Starch",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Purdue University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 19,
      "start_date": "2026-05-01",
      "completion_date": "2026-11-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-10-28T15:06:27.051Z",
      "location_count": 1,
      "location_summary": "West Lafayette, Indiana",
      "locations": [
        {
          "city": "West Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07572513"
    },
    {
      "nct_id": "NCT05287360",
      "title": "A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Rivoceranib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elevar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-12-30",
      "completion_date": "2022-03-24",
      "has_results": false,
      "last_update_posted_date": "2022-04-18",
      "last_synced_at": "2026-10-28T15:06:27.051Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05287360"
    },
    {
      "nct_id": "NCT05304390",
      "title": "A Tailored Screening and Smoking Cessation Program for the LGBTQ Community of Seattle",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Patient Navigation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Smoking Cessation Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Carbon Monoxide Measurement",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2022-06-06",
      "completion_date": "2024-10-28",
      "has_results": false,
      "last_update_posted_date": "2024-12-02",
      "last_synced_at": "2026-10-28T15:06:27.051Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05304390"
    },
    {
      "nct_id": "NCT03107182",
      "title": "Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HPV-Related Squamous Cell Carcinoma",
        "HNSCC"
      ],
      "interventions": [
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Transoral robotic surgery (TORS)",
          "type": "PROCEDURE"
        },
        {
          "name": "Adjuvant RT",
          "type": "RADIATION"
        },
        {
          "name": "Chemoradiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2017-06-27",
      "completion_date": "2024-09-06",
      "has_results": true,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-10-28T15:06:27.051Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03107182"
    },
    {
      "nct_id": "NCT05870579",
      "title": "[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "[68Ga]Ga-NeoB",
          "type": "DRUG"
        },
        {
          "name": "[177Lu]Lu-NeoB",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Goserelin",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 28,
      "start_date": "2023-11-13",
      "completion_date": "2032-05-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-28T15:06:27.051Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Houston, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05870579"
    }
  ]
}